Abstract
Drug resistance is an important obstacle to human leukemia therapeutics. Piperlongumine has previously demonstrated the ability to suppress certain human tumor processes; however, the ability of piperlongumine to reverse the drug resistance of human leukemia and its mechanism of action have not yet been clearly elucidated. In this study, the doxorubicin resistance reversal effect of piperlongumine on K562/A02 human leukemia cells and the underlying mechanism were investigated. The results indicated that piperlongumine promoted doxorubicin sensitivity, apoptosis, the intracellular accumulation of rhodamine-123, the activities of caspase-3 and -8, and the expression of reactive oxygen species, p53, p27 and p-PTEN. Furthermore, it suppressed the expression of P-glycoprotein, MDR1, MRP1, survivin and p-Akt, and the transcriptional activities of NF-κB and twist, and arrested the cell cycle in the G2/M phase. The results indicate that piperlongumine has the potential to be used as a therapeutic agent for human leukemia.
References
Jun 4, 2013·Molecular Oncology·Ji-Ying WangJianxiang Wang
Jul 9, 2013·Molecules and Cells·Min Soo KimWook Jin
Jul 24, 2013·Molecular and Cellular Biochemistry·Nathalia Daflon-YunesVivian M Rumjanek
Oct 4, 2013·The Journal of Biological Chemistry·Shanshan PeiCraig T Jordan
Oct 22, 2013·Haematologica·Ingrid M AriësMonique L den Boer
Oct 23, 2013·Cancer Biology & Therapy·Soheila RahgozarFatemeh Montazeri
Oct 24, 2013·The Prostate·Serge GinzburgVladimir M Kolenko
Nov 5, 2013·The New England Journal of Medicine·James H Doroshow
Nov 5, 2013·Cancer Letters·Joerg ChromikSimone Fulda
Nov 12, 2013·Leukemia Research·Flavia Cunha VasconcelosRaquel Ciuvalschi Maia
Nov 14, 2013·British Journal of Haematology·Valerie PedeBruno Verhasselt
Nov 19, 2013·PloS One·Susanne BaduraOliver G Ottmann
Nov 23, 2013·The Annals of Pharmacotherapy·Caitlin L Shamroe, Jill M Comeau
Dec 18, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xianping ShiJinbao Liu
Jan 5, 2014·British Journal of Haematology·Håkon ReikvamØystein Bruserud
Jan 18, 2014·British Journal of Cancer·P MakhovV M Kolenko
Jan 24, 2014·PloS One·Hongye MaLi Jia
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Hadi KaramiEbrahim Sakhinia
Feb 5, 2014·Anti-cancer Drugs·Zhe LiuHao Liu
Feb 11, 2014·Nature Immunology·Ila JoshiKatia Georgopoulos
Feb 11, 2014·Oncoimmunology·Armen MardirosStephen J Forman
Mar 14, 2014·Nanoscale·Yuanyuan LiuYoufu Luo
Apr 15, 2014·Apoptosis : an International Journal on Programmed Cell Death·Shweta ShrivastavaSistla Ramakrishna
Jul 11, 2014·JAMA Ophthalmology·Alia RashidSuzanne K Freitag
Sep 7, 2014·Biochemical and Biophysical Research Communications·Seong-Su HanNatalie L Kamberos
Citations
Nov 2, 2017·Oncotarget·Ying-Xia NingJian Wang
Feb 13, 2018·Oncology Letters·Yan ShuJing Chen
Feb 6, 2018·Oncology Letters·Yin-Ju ChenJeng-Fong Chiou
Mar 18, 2016·International Journal of Oncology·Jie-Ru ChenYou-Jie Li
Nov 5, 2019·Frontiers in Pharmacology·Chao ZhangXiao-Ping Liu
Nov 30, 2018·Frontiers in Pharmacology·Caiyun LiYuqing Chen
Dec 16, 2020·Cancers·Susana MachadoWolfgang Link
May 1, 2021·European Journal of Medicinal Chemistry·Peng ZhuYong Ling